Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor-derived expanded NK cells
- Development stage
- Unknown
- Lead developer
- Shanghai Enkai Cell Technology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Donor-derived expanded NK cells are an allogeneic cell therapy consisting of natural killer (NK) cells isolated from donor peripheral blood and expanded ex vivo using a feeder-free system. Developed by Shanghai NK CellTech in collaboration with Peking University, these cells are designed to exert potent anti-leukemic activity through direct cytotoxicity against malignant cells. In clinical studies (NCT04221971), these cells have been evaluated in patients with relapsed or minimal residual disease (MRD) positive acute myeloid leukemia (AML) following lymphodepleting chemotherapy with cyclophosphamide and fludarabine. The cells demonstrate the ability to survive in vivo for up to 30 days and can penetrate the central nervous system to target extramedullary disease.
- Other names
- allogeneic NK cell therapyex vivo-expanded NK cellsclinical-grade expanded NK cells
Beyond the preview
Go deeper on donor-derived expanded NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor-derived expanded NK cells.